ReviewClinical and experimental medicine2011
Advances in the understanding of the Fc gamma receptors-mediated autoantibodies uptake.
Review in Clinical and experimental medicine, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
12 citing papers in PubMed, 29 citations in OpenAlex.
- Development and Characterization of a Primary Ciliated Porcine Airway Model for the Evaluation of In Vitro Mucociliary Clearance and Mucosal Drug Delivery.Pharmaceutics · 2025Article
- Characterization of a primary cellular airway model for inhalative drug delivery in comparison with the established permanent cell lines CaLu3 and RPMI 2650.In vitro models · 2024Article
- Cell-in-cell structure mediates in-cell killing suppressed by CD44.Cell discovery · 2022Article
- Detection and functional resolution of soluble immune complexes by an FcγR reporter cell panel.EMBO molecular medicine · 2022Article
- Transcriptome profiling of osteoclast subsets associated with arthritis: A pathogenic role of CCR2Frontiers in immunology · 2022Article
- Single-Cell RNA Sequencing Reveals Cellular and Transcriptional Changes Associated With M1 Macrophage Polarization in Hidradenitis Suppurativa.Frontiers in medicine · 2021Article
- Risk factors for treatment resistance and relapse of Chinese patients with MPO-ANCA-associated vasculitis.Clinical and experimental medicine · 2020Article
- Molecular signatures associated with tumor-specific immune response in melanoma patients treated with dendritic cell-based immunotherapy.Oncotarget · 2018Article
- Neovascularization is prominent in the chronic inflammatory lesions of Sjögren's syndrome.International journal of experimental pathology · 2014Article
- Salivary gland expression level of IκBα regulatory protein in Sjögren's syndrome.Journal of molecular histology · 2013Article
- Targeting cancer with a lupus autoantibody.Science translational medicine · 2012Article
- A failure of TNFAIP3 negative regulation maintains sustained NF-κB activation in Sjögren's syndrome.Histochemistry and cell biology · 2011Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Receptors for the Fc fragment of immunoglobulin G (FcγRs) are important molecules not only to mediate and control the effectors' functions of IgG antibodies, but they also control the autoimmunity-tolerance balance in the periphery. In humans, three different types of FcγRs, belonging to the Ig gene superfamily, have been identified; FcγRI (cluster of differentiation (CD64), FcγRII (CD32) and FcγRIII (CD16). A wide range of inflammatory and autoimmune diseases, such as vasculitis, glomerulonephritis, and autoimmune hemolytic anemia, seems to be mediated, in part, by FcγRs. Recent findings supposed that, under certain conditions, FcγRs are involved in the penetration of antibodies into cells and FcγRs constitute one of the main effector mechanisms through which autoantibodies exert their action. In this review, we concentrate on the role of human FcγRs in autoantibodies penetration and summarize the current knowledge on the structure, ligand binding capacity and their role in autoimmunity and pathogenic effect of autoantibodies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.